Bender, D. A., Nayak, S. M., Siegel, J. S., Hellerstein, D. J., Ercal, B. C., & Lenze, E. J. (2025). Psychological Support Approaches in Psychedelic Therapy. The Journal of Clinical Psychiatry, 86(1). https://doi.org/10.4088/jcp.24m15521

Wang, E., Mathai, D. S., Gukasyan, N., Nayak, S., & Garcia-Romeu, A. (2024). Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-78736-1

Yaden, D. B., Gukasyan, N., & Nayak, S. M. (2024). Psilocybin in Bipolar II Study Provides Preliminary Data on Safety. JAMA Psychiatry, 81(6), 541. https://doi.org/10.1001/jamapsychiatry.2023.4680

Palamar, J. J., Fitzgerald, N. D., Carr, T. H., Rutherford, C., Keyes, K. M., & Cottler, L. B. (2024). National and regional trends in seizures of shrooms (psilocybin) in the United States, 2017–2022. Drug and Alcohol Dependence, 258, 111086. https://doi.org/10.1016/j.drugalcdep.2024.111086

Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., Páleníček, T., Redjep, O., Repantis, D., … Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120–127. https://doi.org/10.1016/j.jad.2023.01.108